0001493152-22-014514.txt : 20220519 0001493152-22-014514.hdr.sgml : 20220519 20220519173025 ACCESSION NUMBER: 0001493152-22-014514 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20220519 ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220519 DATE AS OF CHANGE: 20220519 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CYTRX CORP CENTRAL INDEX KEY: 0000799698 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 581642750 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-15327 FILM NUMBER: 22944329 BUSINESS ADDRESS: STREET 1: 11726 SAN VICENTE BOULEVARD STREET 2: SUITE 650 CITY: LOS ANGELES STATE: CA ZIP: 90049 BUSINESS PHONE: 310-826-5648 MAIL ADDRESS: STREET 1: 11726 SAN VICENTE BOULEVARD STREET 2: SUITE 650 CITY: LOS ANGELES STATE: CA ZIP: 90049 8-K 1 form8-k.htm
0000799698 false --12-31 DE 0000799698 2022-05-19 2022-05-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 19, 2022

 

 

 

CYTRX CORPORATION

(Exact name of registrant as specified in its charter)

 

Delaware   000-15327   58-1642740

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

11726 San Vicente Boulevard, Suite 650

Los Angeles, California 90049

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (310) 826-5648

 

Former name or former address, if changed since last report: None

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(g) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered

Common Stock, par value $0.001 per share Series B Junior Participating Preferred Stock Purchase Rights

  CYTR   OTC Markets

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


 

 

 

 
 

 

Item 3.03. Material Modification to Rights of Security Holders.

 

The disclosure set forth in Item 5.03 below is hereby incorporated herein by reference.

 

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

Series D Preferred Stock

 

On May 19, 2022, the board of directors (the “Board”) of CytRx Corporation (the “Company”) declared a dividend of one one-thousandth of a share of Series D Preferred Stock, par value $0.01 per share (“Series D Preferred Stock”), for each outstanding share of the Company’s common stock, par value $0.001 per share (“Common Stock”) to stockholders of record at 5:00 p.m. Eastern Time on May 20, 2022 (the “Record Date”).

 

General; Transferability. Shares of Series D Preferred Stock will be uncertificated and represented in book-entry form. No shares of Series D Preferred Stock may be transferred by the holder thereof except in connection with a transfer by such holder of any shares of Common Stock held by such holder, in which case a number of one one-thousandths (1/1,000ths) of a share of Series D Preferred Stock equal to the number of shares of Common Stock to be transferred by such holder will be automatically transferred to the transferee of such shares of Common Stock.

 

Voting Rights. Each share of Series D Preferred Stock will entitle the holder thereof to 1,000,000 votes per share (and, for the avoidance of doubt, each fraction of a share of Series D Preferred Stock will have a ratable number of votes). Thus, each one-thousandth of a share of Series D Preferred Stock would entitle the holder thereof to 1,000 votes. The outstanding shares of Series D Preferred Stock will vote together with the outstanding shares of Common Stock of the Company as a single class exclusively with respect to (1) any proposal to adopt an amendment to the Company’s Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), to reclassify the outstanding shares of Common Stock into a smaller number of shares of Common Stock at a ratio specified in or determined in accordance with the terms of such amendment (the “Reverse Stock Split”) and (2) any proposal to adjourn any meeting of stockholders called for the purpose of voting on Reverse Stock Split (the “Adjournment Proposal”). The Series D Preferred Stock will not be entitled to vote on any other matter, except to the extent required under the Delaware General Corporation Law.

 

Unless otherwise provided on any applicable proxy or ballot with respect to the voting on the Reverse Stock Split or the Adjournment Proposal, the vote of each share of Series D Preferred Stock (or fraction thereof) entitled to vote on the Reverse Stock Split, the Adjournment Proposal or any other matter brought before any meeting of stockholders held to vote on the Reverse Stock Split and the Adjournment Proposal will be cast in the same manner as the vote, if any, of the share of Common Stock (or fraction thereof) in respect of which such share of Series D Preferred Stock (or fraction thereof) was issued as a dividend is cast on the Reverse Stock Split, the Adjournment Proposal or such other matter, as applicable, and the proxy or ballot with respect to shares of Common Stock held by any holder on whose behalf such proxy or ballot is submitted will be deemed to include all shares of Series D Preferred Stock (or fraction thereof) held by such holder. Holders of Series D Preferred Stock will not receive a separate ballot or proxy to cast votes with respect to the Series D Preferred Stock on the Reverse Stock Split, the Adjournment Proposal or any other matter brought before any meeting of stockholders held to vote on the Reverse Stock Split.

 

 
 

 

Dividend Rights. The holders of Series D Preferred Stock, as such, will not be entitled to receive dividends of any kind.

 

Liquidation Preference. The Series D Preferred Stock will rank senior to the Common Stock as to any distribution of assets upon a liquidation, dissolution or winding up of the Company, whether voluntarily or involuntarily (a “Dissolution”). Upon any Dissolution, each holder of outstanding shares of Series D Preferred Stock will be entitled to be paid out of the assets of the Company available for distribution to stockholders, prior and in preference to any distribution to the holders of Common Stock, an amount in cash equal to $0.01 per outstanding share of Series D Preferred Stock.

 

Redemption. All shares of Series D Preferred Stock that are not present in person or by proxy at any meeting of stockholders held to vote on the Reverse Stock Split and the Adjournment Proposal as of immediately prior to the opening of the polls at such meeting (the “Initial Redemption Time”) will automatically be redeemed in whole, but not in part, by the Company at the Initial Redemption Time without further action on the part of the Company or the holder of shares of Series D Preferred Stock (the “Initial Redemption”). Any outstanding shares of Series D Preferred Stock that have not been redeemed pursuant to an Initial Redemption will be redeemed in whole, but not in part, (i) if such redemption is ordered by the Board in its sole discretion, automatically and effective on such time and date specified by the Board in its sole discretion or (ii) automatically upon the approval by the Corporation’s stockholders of the Reverse Stock Split at any meeting of the stockholders held for the purpose of voting on such proposal.

 

Each share of Series D Preferred Stock redeemed in any redemption described above will be redeemed in consideration for the right to receive an amount equal to $0.10 in cash for each ten whole shares of Series D Preferred Stock that are “beneficially owned” by the “beneficial owner” (as such terms are defined in the certificate of designation with respect to the Series D Preferred Stock (the “Certificate of Designation”)) thereof as of immediately prior to the applicable redemption time and redeemed pursuant to such redemption. However, the redemption consideration in respect of the shares of Series D Preferred Stock (or fractions thereof) redeemed in any redemption described above: (i) will entitle the former beneficial owners of less than ten whole shares of Series D Preferred Stock redeemed in any redemption to no cash payment in respect thereof and (y) will, in the case of a former beneficial owner of a number of shares of Series D Preferred Stock (or fractions thereof) redeemed pursuant to any redemption that is not equal to a whole number that is a multiple of ten, entitle such beneficial owner to the same cash payment, if any, in respect of such redemption as would have been payable in such redemption to such beneficial owner if the number of shares (or fractions thereof) beneficially owned by such beneficial owner and redeemed pursuant to such redemption were rounded down to the nearest whole number that is a multiple of ten (such, that for example, the former beneficial owner of 25 shares of Series D Preferred Stock redeemed pursuant to any redemption will be entitled to receive the same cash payment in respect of such redemption as would have been payable to the former beneficial owner of 20 shares of Series D Preferred Stock redeemed pursuant to such redemption).

 

The Series D Preferred Stock is not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company. The Series D Preferred Stock has no stated maturity and is not subject to any sinking fund. The Series D Preferred Stock is not subject to any restriction on the redemption or repurchase of shares by the Company while there is any arrearage in the payment of dividends or sinking fund installments.

 

The Certificate of Designation was filed with the Delaware Secretary of State and became effective on May 19, 2022. The foregoing description of the Series D Preferred Stock does not purport to be complete and is qualified in its entirety by reference to the Certificate of Designation, a copy of which is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated by reference herein.

 

 
 

 

Amendment of By-laws

 

On May 19, 2022, the Board approved an amendment to the Amended and Restated By-Laws of the Company (the “Amendment”), which will be effective as of May 19, 2022. The Amendment amends and restates the paragraph titled “Quorum” in Section 3 of Article II of the Company’s existing Amended and Restated By-Laws in its entirety to lower the number of shares of outstanding stock represented at a meeting of stockholders constituting a quorum, in person or by proxy, from a “majority of the outstanding shares or stock” to “one-third of the outstanding shares of stock entitled to vote”. Specifically, the restated paragraph states: “QUORUM. The holders of one-third of the outstanding shares of stock entitled to vote thereat shall constitute a quorum at a meeting of stockholders for the transaction of any business, but if at any meeting there shall be less than a quorum present, the chairman of the meeting may, to the extent permitted by law, adjourn the meeting from time to time until a quorum shall be present or represented.”

 

The foregoing description of the Amendment is qualified in its entirety by reference to the full text of the Amendment, a copy of which is filed as Exhibit 3.2 to this Current Report on Form 8-K and is incorporated by reference herein.

 

Certificate of Correction

 

On May 19, 2022, the Company filed a certificate of correction (the “Certificate of Correction”) to the Certificate of Amendment to Restated Certificate of Incorporation of CytRx Corporation filed on March 16, 2022 (the “March Amendment”) with the Secretary of State of the State of Delaware. The March Amendment erroneously stated that the par value per share of the Company’s preferred stock is $0.1 per share. The par value per share of the Company’s preferred stock should have been stated as being $0.01 per share. The Certificate of Correction corrects this scrivener’s error to the March Amendment by modifying the first paragraph of Article FOURTH of the March Amendment to correctly state that the par value per share of Company’s preferred stock is $0.01 per share.

 

The foregoing description of the Certificate of Correction is qualified in its entirety by reference to the full text of the Certificate of Correction, a copy of which is filed as Exhibit 3.3 to this Current Report on Form 8-K and is incorporated by reference herein.

 

Item 7.01. Regulation FD Disclosure.

 

On May 19, 2022, the Company issued a press release announcing the Series D Preferred Stock dividend. A copy of that press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

 

In accordance with General Instruction B.2 of Form 8-K, the information in Exhibit 99.1, which is incorporated into this Item 7.01, is being furnished pursuant to Item 7.01 and shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended, except as shall be expressly set forth by reference in such a filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
3.1   Certificate of Designation of the Series D Preferred Stock of the Company, dated May 19, 2022 (incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement on Form 8-A, filed with the Securities and Exchange Commission on May 19, 2022, File No. 000-15327)
3.2   Amendment to the Amended and Restated By-laws of CytRx Corporation, dated May 19, 2022
3.3   Certificate of Correction, dated May 19, 2022 to the Certificate of Amendment to Restated Certificate of Incorporation of CytRx Corporation filed on March 16, 2022
99.1   Press Release, issued May 19, 2022 (furnished pursuant to Item 7.01)
104   Cover Page Interactive Data File (formatted as Inline XBRL)

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  CYTRX CORPORATION
   
Date: May 19, 2022 /s/ John Y. Caloz
  John Y. Caloz
  Chief Financial Officer

 

 

 

 

 

 EX-3.2 2 ex3-2.htm

 

eXHIBIT 3.2

 

Amendment to the Amended and Restated By-laws

of CytRx Corporation

 

Pursuant to Article Ninth of the Restated Certificate of Incorporation of CytRx Corporation, a Delaware corporation (the “Company”), Article VIII of the Amended and Restated By-laws of the Company (as amended heretofore, the “By-laws”) of the Corporation, and Section 109 of the General Corporation Law of the State of Delaware, on the date hereof, the By-laws of the Company are hereby amended as follows:

 

The paragraph titled “QUORUM” in Section 3 of Article II is hereby deleted in its entirety and replaced with the following By-law:

 

“QUORUM. The holders of one-third of the outstanding shares of stock entitled to vote thereat shall constitute a quorum at a meeting of stockholders for the transaction of any business, but if at any meeting there shall be less than a quorum present, the chairman of the meeting may, to the extent permitted by law, adjourn the meeting from time to time until a quorum shall be present or represented.”

 

IN WITNESS WHEREOF, this amendment to the By-laws of the Company is executed on May 19, 2022.

 

  By: /s/ John Y. Caloz
  Name: John Y. Caloz
  Title: Chief Financial Officer

 

 

 

 

 

 EX-3.3 3 ex3-3.htm

 

EXHIBIT 3.3

 

STATE OF DELAWARE
CERTIFICATE OF CORRECTION

 

CytRx Corporation, a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify as follows:

 

1.The name of the corporation is CytRx Corporation.
   
2.That a Certificate of Amendment to Restated Certificate of Incorporation of CytRx Corporation (the “Certificate”) was filed with the Secretary of State of Delaware on March 16, 2022 and that said Certificate requires correction as permitted by Section 103 of the General Corporation Law of the State of Delaware.
   
3.The inaccuracy or defect of said Certificate is: The first paragraph of Article FOURTH incorrectly states that the par value per share of CytRx Corporation preferred stock is $0.1 per share, when it should state that such par value is $0.01 per share.
   
4.The Article FOURTH of the Certificate is corrected to read as follows:

 

“FOURTH. The total number of shares of all classes of stock that the corporation shall have the authority to issue is Sixty-Three Million Two Hundred Twenty-Seven Thousand Two-Hundred Seventy-Three (63,227,273), of which Sixty-Two Million Three Hundred Ninety-Three Thousand Nine Hundred Forty (62,393,940) shall be common stock, par value $0.001 per share (the “Common Stock”), and Eight Hundred Thirty-Three Thousand Three Hundred Thirty-Three (833,333) shall be preferred stock, par value $0.01 per share (the “Preferred Stock”).

 

The Board of Directors is hereby authorized, subject to any limitations prescribed by law, to provide for the issuance of the shares of Preferred Stock in series, and by filing a Certificate pursuant to the applicable law of the State of Delaware (hereinafter referred to as a “Preferred Stock Designation”), to establish from time to time the number of shares to be included in each such series, and to fix the designations, powers, preferences, and rights of the shares of each such series, any qualifications, limitations or restrictions thereof.”

 

IN WITNESS WHEREOF, said corporation has caused this Certificate of Correction this 19th day of May, 2022.

 

  By: /s/ John Y. Caloz
  Name: John Y. Caloz
  Title: Chief Financial Officer

 

 

 

 

 EX-99.1 4 ex99-1.htm

 

Exhibit 99.1

 

CytRx Announces Distribution of Series D Preferred Stock to
Holders of its Common Stock

 

LOS ANGELES May 19, 2022, CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series D Preferred Stock, par value $0.01 per share, for each outstanding share of the Company’s common stock held of record as of 5:00 pm Eastern Time on May 20, 2022. The outstanding shares of Series D Preferred Stock will vote together with the outstanding shares of the Company’s common stock, as a single class, exclusively with respect to a proposal to give the Company’s Board of Directors discretion to implement a reverse stock split in connection with satisfying the initial listing requirements of a national securities exchange, as well as any proposal to adjourn any meeting of stockholders called for the purpose of voting on the reverse stock split, and will not be entitled to vote on any other matter, except to the extent required under the Delaware General Corporation Law. Subject to certain limitations, each outstanding share of Series D Preferred Stock will have 1,000,000 votes per share (or 1,000 votes per one one-thousandth of a share of Series D Preferred Stock).

 

All shares of Series D Preferred Stock that are not present in person or by proxy at the meeting of stockholders held to vote on the reverse stock split as of immediately prior to the opening of the polls at such meeting will automatically be redeemed by the Company. Any outstanding shares of Series D Preferred Stock that have not been so redeemed will be redeemed if such redemption is ordered by the Company’s Board of Directors or automatically upon the approval by the Company’s stockholders of an amendment to the Company’s certificate of incorporation effecting the reverse stock split at such meeting.

 

The Series D Preferred Stock will be uncertificated, and no shares of Series D Preferred Stock will be transferable by any holder thereof except in connection with a transfer by such holder of any shares of the Company’s common stock held by such holder. In that case, a number of one one-thousandths of a share of Series D Preferred Stock equal to the number of shares of the Company’s common stock to be transferred by such holder would be transferred to the transferee of such shares of common stock.

 

Further details regarding the Series D Preferred Stock will be contained in a report on Form 8-K to be filed by the Company with the Securities and Exchange Commission.

 

 
 

 

Forward-Looking Statements

 

This press release may contain certain statements relating to future results which are forward-looking statements. These statements are not historical facts, but instead represent only CytRx’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of CytRx’s control. Forward-looking statements often include words such as “anticipates,” “estimates,” “expects,” “projects,” “forecasts”, “intends,” “plans,” “believes”, “suggest”, “estimate”, “target”, “should”, “could”, “would”, “may”, “might”, or “will” and words and terms of similar import. Forward-looking statements involve known and unknown risks, uncertainties and other factors, many of which are outside our control. Forward-looking statements include, but are not limited to, statements about our market opportunity and the potential growth of that market, potential receipt of EMA and FDA approvals, potential receipt of future milestone and royalty payments, our strategies (including with regard to stock splits), and trends in our industry and markets, all of which may be affected by, among others, adverse changes in general economic and market conditions. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements; and other risks and uncertainties described in the most recent annual and quarterly reports filed by the CytRx with the SEC, including disclosures under the heading “Risk Factors”, and current reports filed since the date of the CytRx’s most recent annual report. All forward-looking statements are based upon information available to the CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

About CytRx

 

CytRx Corporation (OTCQB: CYTR) is a biopharmaceutical company with expertise in discovering and developing new therapeutics principally to treat patients with cancer. CytRx’s most recent advanced drug conjugate, aldoxorubicin, is an improved version of the widely used anti-cancer drug doxorubicin and has been out-licensed to ImmunityBio, Inc. In addition, CytRx’s drug candidate, arimoclomol, was sold to Orphazyme A/S in exchange for milestone payments and royalties. Orphazyme is developing arimoclomol in two indications, including Niemann-Pick disease Type C (NPC), and Gaucher disease. CytRx Corporation’s website is www.cytrx.com.

 

Contacts

 

Longacre Square Partners

Greg Marose / Bela Kirpalani

cytrx@longacresquare.com

 

 

 

 

 

 EX-101.SCH 5 cytr-20220519.xsd 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 6 cytr-20220519_lab.xml Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Entity Information, Former Legal or Registered Name Common Stock 0.001 Par Value Per Share [Member] Series B Junior Participating Preferred Stock Purchase Rights [Member] EX-101.PRE 7 cytr-20220519_pre.xml XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover
May 19, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 19, 2022
Current Fiscal Year End Date --12-31
Entity File Number 000-15327
Entity Registrant Name CYTRX CORPORATION
Entity Central Index Key 0000799698
Entity Tax Identification Number 58-1642740
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 11726 San Vicente Boulevard
Entity Address, Address Line Two Suite 650
Entity Address, City or Town Los Angeles
Entity Address, State or Province CA
Entity Address, Postal Zip Code 90049
City Area Code (310)
Local Phone Number 826-5648
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share Series B Junior Participating Preferred Stock Purchase Rights
Trading Symbol CYTR
Entity Emerging Growth Company false
Entity Information, Former Legal or Registered Name None
XML 9 form8-k_htm.xml IDEA: XBRL DOCUMENT 0000799698 2022-05-19 2022-05-19 iso4217:USD shares iso4217:USD shares 0000799698 false --12-31 DE 8-K 2022-05-19 CYTRX CORPORATION 000-15327 58-1642740 11726 San Vicente Boulevard Suite 650 Los Angeles CA 90049 (310) 826-5648 None false false false false Common Stock, par value $0.001 per share Series B Junior Participating Preferred Stock Purchase Rights CYTR false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://cytrx.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm cytr-20220519.xsd cytr-20220519_lab.xml cytr-20220519_pre.xml ex3-2.htm ex3-3.htm ex99-1.htm http://xbrl.sec.gov/dei/2022 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "cytr-20220519_lab.xml" ] }, "presentationLink": { "local": [ "cytr-20220519_pre.xml" ] }, "schema": { "local": [ "cytr-20220519.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 60, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "CYTR", "nsuri": "http://cytrx.com/20220519", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-05-19to2022-05-19", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://cytrx.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-05-19to2022-05-19", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 17 0001493152-22-014514-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-014514-xbrl.zip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